Aktie 688222 HITGEN INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen HitGen Inc.

Aktien

688222

CNE1000040G3

688222

Schlusskurs Shanghai S.E.
Andere Börsenplätze
 00:00:00 16.05.2024 		% 5 Tage % 1. Jan.
13,04 CNY 0,00 % Intraday Chart für HitGen Inc. -5,78 % -13,01 %
24.04. HitGen Inc. meldet Ergebnis für das erste Quartal bis zum 31. März 2024 CI
23.02. HitGen Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
HitGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
HitGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
HitGen Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023
Chengdu HitGen and the Structural Genomics Consortium have reached A Cooperation in the research and development of new drugs based on DEL technology Release time, 2023-09-28
HitGen Receives 10 Million Yuan in Government Subsidies
The Structural Genomics Consortium and HitGen Inc. Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery
Pierre Fabre Laboratories and Vernalis announce a drug discovery collaboration in oncology
HitGen Inc.(XSSC:688222) added to S&P Global BMI Index
HitGen Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
Chengdu Hittech and Nested Therapeutics signed a new drug research and development service contract based on DEL technology
HitGen Inc. Enters into DNA-Encoded Library Based Research Service Agreement with Nested Therapeutics, Inc
HitGen Inc. Launches A Newly Upgraded Version of OpenDELâ„¢, A Self-Service Screening Kit, to Facilitate Innovative Drug Discovery Research
HitGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Certain A Shares of HitGen Inc. are subject to a Lock-Up Agreement Ending on 16-APR-2023.
HitGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Tranche Update on HitGen Inc.'s Equity Buyback Plan announced on July 1, 2022.
HitGen Inc.'s Equity Buyback announced on July 1, 2022, has expired with 1,238,700 shares, representing 0.34% for CNY 20 million.
HitGen Inc. Announces Research Agreement with Nitrase Therapeutics, Inc. Focused on DNA-Encoded Library Based Drug Discovery
DAEWOONG PHARMACEUTICAL Co., Ltd and HitGen Inc. Announces Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery
HitGen Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 688222 Aktie
  4. Nachrichten HitGen Inc.
  5. Andere Sprachen